Armodafinil
Nuvigil
Armodafinil (Nuvigil) is the longer-lasting R-enantiomer of racemic modafinil, a non-amphetamine wakefulness-promoting eugeroic approved for excessive sleepiness in obstructive sleep apnea (as an adjunct to CPAP), shift work disorder, and narcolepsy. It is widely used off-label as a cognitive/alertness "smart drug." Although often marketed as low-risk, human PET imaging shows it (via modafinil) blocks dopamine transporters and raises dopamine in the nucleus accumbens, so it is not free of dependence/abuse potential; it is a Schedule IV controlled substance. It has mild sympathomimetic cardiovascular effects (small blood pressure/heart rate increases), commonly causes headache, nausea, anxiety and insomnia, can trigger or worsen psychiatric symptoms, and induces CYP3A4 enough to reduce the efficacy of hormonal contraceptives. Rare but serious hypersensitivity/skin reactions are described in product labeling. Much of the rare-event and long-term safety picture is extrapolated from modafinil rather than armodafinil-specific trials. This is harm-reduction reference information, not medical advice or an endorsement of use.
Mechanism of action
Pharmacokinetics
Mean terminal elimination half-life approximately 13-16.5 hours in humans (the R-isomer component ~15 h; note racemic modafinil's S-isomer is shorter at 4-5 h). Longer effective daytime exposure than mg-equivalent modafinil.
Once-daily dosing; wakefulness effect sustained across the working day, with armodafinil maintaining plasma concentrations above the pharmacodynamic threshold longer than modafinil late in the dose interval.
Oral (tablet).
Extensively hepatically metabolized, primarily by amide hydrolysis with a minor CYP3A4/5 oxidative pathway; renal excretion of unchanged drug is minor. It is a modest CYP3A4 inducer and CYP2C19 inhibitor. Half-life/exposure data are provided for monitoring and washout planning (roughly 3 days for near-complete elimination), not to evade testing; severe hepatic impairment prolongs exposure and requires dose reduction.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Promotes wakefulness and reduces excessive daytime sleepiness (measured objectively by Maintenance of Wakefulness Test) in obstructive sleep apnea, shift work disorder, and narcolepsy
- Improves patient- and clinician-rated sleepiness (Epworth Sleepiness Scale, Clinical Global Impression of Change) and reduces global fatigue
- Maintains higher plasma concentrations later in the day than milligram-equivalent modafinil, giving sustained daytime alertness
- Does not disrupt nighttime sleep architecture on polysomnography at therapeutic doses
- Widely used off-label for alertness/cognitive enhancement, though this use is not an approved indication and evidence outside sleep disorders is weaker
Adverse effects by system
Mild sympathomimetic effects: small, usually clinically insignificant increases in blood pressure and heart rate; clinically significant BP elevations were infrequent (<1%) in pooled modafinil safety data. Dizziness is common. Caution and monitoring advised in anyone with hypertension or cardiac disease.
No signal of clinically meaningful hepatotoxicity in controlled data; abnormal laboratory values (including liver-related) occurred in fewer than 1% of modafinil-treated patients. The drug is hepatically metabolized, so severe pre-existing hepatic impairment warrants dose reduction and clinician oversight.
Not a hormonal agent and no direct hypothalamic-pituitary-gonadal (HPTA) suppression is described. The clinically important endocrine interaction is enzyme induction (CYP3A4) that lowers exposure to ethinyl estradiol and can reduce hormonal contraceptive efficacy.
No direct gonadal toxicity described. The principal reproductive-relevant risk is reduced effectiveness of hormonal contraceptives via CYP3A4 induction, creating unintended-pregnancy risk. Pregnancy safety is not established.
Anxiety, insomnia, nervousness, and headache are common; can precipitate or worsen anxiety, agitation, mania, psychosis, and suicidal ideation, particularly in people with underlying psychiatric illness. Because it raises accumbal dopamine, abuse/dependence potential exists.
No specific nephrotoxicity established in the retrieved human literature; renal excretion of unchanged drug is minor. No adequate armodafinil-specific renal-outcome data.
No clinically significant hematologic toxicity established; clinically meaningful lab abnormalities were rare (<1%) in pooled modafinil safety data. No adequate armodafinil-specific hematologic data.
Common: none serious at usual rates beyond nonspecific reactions. Serious hypersensitivity reactions and severe rash (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS) are described in modafinil/armodafinil product labeling; no adequate armodafinil-specific primary trial data were retrieved to quantify incidence. Any rash should prompt immediate discontinuation and medical evaluation.
HPTA suppression & recovery
Suppression: None expected — armodafinil is a eugeroic, not a hormonal or anabolic agent, and does not suppress the HPTA axis.
No HPTA recovery protocol is indicated because there is no meaningful axis suppression, and no SERM (single-agent or otherwise) is warranted for this compound. The relevant endocrine caution is reduced hormonal-contraceptive efficacy via CYP3A4 induction (PMID 11823757), not gonadal suppression. Anyone with genuine endocrine or fertility concerns should consult an endocrinologist rather than self-manage.
Monitoring
Cadence: Baseline before starting; reassess blood pressure and psychiatric/sleep status within the first few weeks and periodically thereafter; any new rash or psychiatric change warrants immediate evaluation rather than waiting for a scheduled visit.
- Any skin rash, mucosal lesions, blistering, or facial swelling — stop immediately and seek urgent care (possible SJS/TEN/DRESS)
- Chest pain, palpitations, or markedly elevated blood pressure
- New or worsening anxiety, agitation, mania, hallucinations, or suicidal thoughts
- Severe or persistent headache, insomnia, or dizziness
- Signs of a hypersensitivity/multi-organ reaction (fever, lymphadenopathy, organ dysfunction)
- Contraceptive failure risk (breakthrough bleeding) if using hormonal birth control
Contraindications
- Known hypersensitivity to armodafinil or modafinil, or prior rash/hypersensitivity reaction to either
- History of serious skin reaction (Stevens-Johnson syndrome, TEN, DRESS) with modafinil/armodafinil
- Clinically significant mitral valve prolapse or left ventricular hypertrophy / recent myocardial ischemia (stimulant-type cardiac caution per labeling)
- Uncontrolled hypertension or significant cardiovascular disease without clinician supervision
- History of psychosis, mania, or unstable psychiatric illness (relative, risk of exacerbation)
- History of stimulant/substance use disorder (abuse/dependence potential)
- Reliance on hormonal contraception without a backup non-hormonal method
- Severe hepatic impairment (dose reduction required; specialist oversight)
- Pregnancy/breastfeeding (safety not established)
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- This is not an endorsement of use; the safest option for non-medical alertness is adequate sleep, and excessive sleepiness should be evaluated by a clinician because it can signal a serious underlying disorder.
- Stop the drug immediately and seek urgent medical care for any rash, blistering, mouth sores, facial swelling, or fever with malaise — these can herald life-threatening skin/hypersensitivity reactions.
- If you rely on hormonal contraception (pill, patch, ring, implant), use an additional non-hormonal method during use and for about a month after stopping, because armodafinil can reduce contraceptive effectiveness.
- It is a controlled substance with real dependence/abuse potential via dopamine pathways; escalating dose, craving, or using it to stay awake beyond safe limits are signals to stop and seek help.
- Do not use it to override sleep for extended periods; masking sleepiness while driving or operating machinery does not restore true alertness and residual sleepiness can persist.
- Monitor blood pressure, especially if you have hypertension or take other stimulants; seek care for chest pain, palpitations, or a hypertensive response.
- Stop and consult a clinician for new or worsening anxiety, agitation, mania, hallucinations, or suicidal thoughts.
- Discuss all other medications with a pharmacist or physician because CYP3A4 induction and CYP2C19 effects can alter levels of many drugs.
- Avoid combining with other stimulants or high caffeine loads, which compounds cardiovascular and anxiety/insomnia risk.
- Endocrine, cardiac, or psychiatric concerns should be managed with the relevant specialist rather than self-managed.
Citations (9)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Armodafinil is the R-enantiomer of racemic modafinil, a non-amphetamine wakefulness-promoting agent; R- and S-isomers are equipotent, and armodafinil maintains higher plasma concentrations later in the day.
- 02
Both armodafinil and modafinil have a mean single-dose terminal elimination half-life of approximately 13 hours; armodafinil produces 33-40% higher AUC than modafinil on a mg-to-mg basis due to monophasic vs biphasic decline.
- 03
In treated OSA patients, armodafinil terminal half-life averaged ~16.5 h (R-isomer ~15 h; S-isomer 4-5 h) with greater systemic exposure than modafinil; most common adverse events with armodafinil were headache (29%), diarrhea (12%), nausea (10%), and dizziness (10%).
- 04
Armodafinil 150 or 250 mg daily as an adjunct to CPAP significantly improved objective wakefulness (MWT), Epworth Sleepiness Scale, clinical global impression, and fatigue over 12 weeks in residual excessive sleepiness of OSA, without disrupting nighttime sleep; common adverse events were headache, nausea, insomnia, anxiety, and dizziness.
- 05
Armodafinil improves wakefulness in excessive sleepiness associated with shift work disorder, consistent across randomized double-blind placebo-controlled trial data.
- 06
In a pooled analysis of 6 randomized, double-blind, placebo-controlled modafinil trials (n=1529), the drug was well tolerated; clinically significant blood-pressure increases were infrequent (<1%), ECG/heart-rate changes were rare, laboratory abnormalities occurred in <1%, and sleep architecture was unaffected; headache and nausea were the most common adverse events.
Meta-analysisPMID 17993041 ↗
- 07
At therapeutic oral doses (200-400 mg), modafinil blocks dopamine transporters and increases extracellular dopamine in the human brain including the nucleus accumbens, indicating potential for abuse and dependence.
- 08
Modafinil induces CYP3A4/5 in humans in vivo and reduces exposure to ethinyl estradiol, creating potential for reduced hormonal contraceptive efficacy and drug-drug interactions.
- 09
Modafinil exerts sympathomimetic/alerting effects including increases in blood pressure and heart rate in controlled human testing.
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice